Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 20/20 | 0.48 |
| ▸ | CDK2 | P24941 | 20/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 20/20 | 0.48 |
| ▸ | AURKA | O14965 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430503 | 0.82 | MAP3K14 (0.31) | — | |
| SCHEMBL429404 | 0.81 | PLK1 (0.49) | CCNA2CDK2CCNA1AURKA | |
| SCHEMBL425480 | 0.81 | CCNA2 (0.47) | CCNA2CDK2CCNA1AURKA | |
| SCHEMBL428547 | 0.80 | ALDH1A1 (0.35) | CCNA2CDK2CCNA1 | |
| SCHEMBL425417 | 0.76 | MAPKAPK2 (0.49) | CCNA2CDK2CCNA1AURKA | |
| SCHEMBL424775 | 0.76 | MAPKAPK2 (0.54) | CCNA2CDK2CCNA1AURKA | |
| SCHEMBL427819 | 0.76 | MAPKAPK2 (0.46) | — | |
| SCHEMBL430537 | 0.76 | MAPKAPK2 (0.36) | — | |
| SCHEMBL426093 | 0.75 | MAPKAPK2 (0.47) | — | |
| SCHEMBL430202 | 0.74 | PTPN11 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2012-01-26 | — | — | US | disclosed |
| US-7838674-B2 | 2-(1-amino-cyclobutylmethyl)-8-(4-methoxy-phenyl)-4,5-dihydro-1 H-1,7,9-triazacyclopenta[a]naph-thalene-3-carboxylic acid lactame; useful especially as inhibitors of mitogen-activated protein kinase-activated protein kinase-2 (MK2 or MAPKAP kinase-2 | NOVARTIS AG (CH) | 2010-11-23 | — | — | US | disclosed |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | NOVARTIS AG | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022030-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | CCNA2 23/4885CDK2 32/4885CCNA1 175/4885 |
| US-20090098218-A1 | Tetracyclic Lactame Derivatives | TNF, RPS6KB2, RPS6KA2 | CCNA2 23/4885CDK2 32/4885CCNA1 175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.